Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020.
This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA.
This is in no way a thorough analysis of OMER's pipeline or even just the potential of Narsoplimab (as it has huge potential in other indications).
Following are all the known companies currently developing a competing treatment.
Alexion Pharmaceuticals
Alexion (ALXN) is the behemoth with a $25B market cap and billions of cash at hand. They